Inhibition of Tau Aggregation by Three Aspergillus nidulans Secondary Metabolites: 2,omega-Dihydroxyemodin, Asperthecin, and Asperbenzaldehyde

doi:10.1055/s-0033-1360180

CNU IR > Pharmacy and Science > Dept. of Pharmacy > Periodical Articles > Item 310902800/28606

Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/28606

Title:	Inhibition of Tau Aggregation by Three Aspergillus nidulans Secondary Metabolites: 2,omega-Dihydroxyemodin, Asperthecin, and Asperbenzaldehyde
Authors:	Paranjape, Smita R. Chiang, Yi-Ming Sanchez, James F. Entwistle, Ruth Wang, Clay C. C. Oakley, Berl R. Gamblin, T. Chris
Contributors:	藥學系
Keywords:	tau microtubule-associated protein Trichocomaceae Aspergillus nidulans Alzheimers disease
Date:	2014-01
Issue Date:	2015-05-06 21:22:17 (UTC+8)
Publisher:	Georg Thieme Verlag Kg
Abstract:	The aggregation of the microtubule-associated protein tau is a significant event in many neurodegenerative diseases including Alzheimers disease. The inhibition or reversal of tau aggregation is therefore a potential therapeutic strategy for these diseases. Fungal natural products have proven to be a rich source of useful compounds having wide varieties of biological activity. We have screened Aspergillus nidulans secondary metabolites containing aromatic ring structures for their ability to inhibit tau aggregation in vitro using an arachidonic acid polymerization protocol and the previously identified aggregation inhibitor emodin as a positive control. While several compounds showed some activity, 2,-dihydroxyemodin, asperthecin, and asperbenzaldehyde were potent aggregation inhibitors as determined by both a filter trap assay and electron microscopy. In this study, these three compounds were stronger inhibitors than emodin, which has been shown in a prior study to inhibit the heparin induction of tau aggregation with an IC50 of 1-5 mu M. Additionally, 2,-dihydroxyemodin, asperthecin, and asperbenzaldehyde reduced, but did not block, tau stabilization of microtubules. 2,-Dihydroxyemodin and asperthecin have similar structures to previously identified tau aggregation inhibitors, while asperbenzaldehyde represents a new class of compounds with tau aggregation inhibitor activity. Asperbenzaldehyde can be readily modified into compounds with strong lipoxygenase inhibitor activity, suggesting that compounds derived from asperbenzaldehyde could have dual activity. Together, our data demonstrates the potential of 2,-dihydroxyemodin, asperthecin, and asperbenzaldehyde as lead compounds for further development as therapeutics to inhibit tau aggregation in Alzheimers disease and neurodegenerative tauopathies.
Relation:	Planta Medica, v.80 n.1, pp.77-85
Appears in Collections:	[Dept. of Pharmacy] Periodical Articles

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	1824	View/Open

Loading...